Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

NCT06920771

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2024-09-09

PhasePHASE3

Study timeline

Study start (actual)2024-09-09Date precision: day

Registry last updated2026-08-10

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

House Dust Mite Allergyunresolved

House Dust Mite Rhinitisunresolved

Interventions

PURETHAL Mites 50,000 AUeq/mlBIOLOGICAL

Biological/Vaccine: PlaceboBIOLOGICAL

Sponsors & collaborators

HAL Allergylead sponsor

Ergomedcollaborator

ClinCompetence Cologne GmbHcollaborator

Mapped research locations

LodzPoland4 LublinPoland4 WarsawPoland3 KrakowPoland3 SofiaBulgaria3 PoznanPoland3 BialystokPoland3 WroclawPoland2 KatowicePoland2 RigaLatvia2 BerlinGermany1 DresdenGermany1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06920771 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.